Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDS NASDAQ:EFTR NYSE:NAVB NASDAQ:TRVN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDSAridis Pharmaceuticals$0.00+1,300.0%$0.00$0.00▼$0.05$149K49.4810,579 shs2,550 shsEFTReFFECTOR Therapeutics$0.00$0.00$0.00▼$0.02$1K2.45,672 shsN/ANAVBNavidea Biopharmaceuticals$0.00$0.00▼$0.05$10K1.767,146 shs992 shsTRVNTrevena$0.01$0.01$0.00▼$1.28$11K0.53799 shs368 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDSAridis Pharmaceuticals0.00%0.00%0.00%-92.86%+100.00%EFTReFFECTOR Therapeutics0.00%0.00%0.00%0.00%0.00%NAVBNavidea Biopharmaceuticals0.00%0.00%0.00%0.00%-71.43%TRVNTrevena0.00%0.00%0.00%0.00%-99.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDSAridis Pharmaceuticals$0.00+1,300.0%$0.00$0.00▼$0.05$149K49.4810,579 shs2,550 shsEFTReFFECTOR Therapeutics$0.00$0.00$0.00▼$0.02$1K2.45,672 shsN/ANAVBNavidea Biopharmaceuticals$0.00$0.00▼$0.05$10K1.767,146 shs992 shsTRVNTrevena$0.01$0.01$0.00▼$1.28$11K0.53799 shs368 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDSAridis Pharmaceuticals0.00%0.00%0.00%-92.86%+100.00%EFTReFFECTOR Therapeutics0.00%0.00%0.00%0.00%0.00%NAVBNavidea Biopharmaceuticals0.00%0.00%0.00%0.00%-71.43%TRVNTrevena0.00%0.00%0.00%0.00%-99.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDSAridis Pharmaceuticals 0.00N/AN/AN/AEFTReFFECTOR Therapeutics 0.00N/AN/AN/ANAVBNavidea Biopharmaceuticals 0.00N/AN/AN/ATRVNTrevena 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDSAridis PharmaceuticalsN/AN/AN/AN/AN/AN/AEFTReFFECTOR TherapeuticsN/AN/AN/AN/A($1.94) per shareN/ANAVBNavidea Biopharmaceuticals$8.13K0.00N/AN/AN/ANaNTRVNTrevena$443K0.02N/AN/A($11.07) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDSAridis Pharmaceuticals-$30.37M$0.090.03N/AN/AN/AN/AN/A6/12/2026 (Estimated)EFTReFFECTOR Therapeutics-$35.81M-$13.08N/AN/AN/AN/AN/AN/A5/8/2026 (Estimated)NAVBNavidea Biopharmaceuticals-$15.18M-$0.21N/AN/AN/AN/AN/AN/AN/ATRVNTrevena-$40.29M-$47.04N/AN/AN/AN/AN/A-119.55%5/13/2026 (Estimated)Latest EFTR, ARDS, TRVN, and NAVB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026N/AEFTReFFECTOR Therapeutics-$6.3960N/AN/AN/A$0.10 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARDSAridis PharmaceuticalsN/AN/AN/AN/AN/AEFTReFFECTOR TherapeuticsN/AN/AN/AN/AN/ANAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/ATRVNTrevenaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDSAridis PharmaceuticalsN/AN/AN/AEFTReFFECTOR TherapeuticsN/AN/AN/ANAVBNavidea BiopharmaceuticalsN/AN/AN/ATRVNTrevenaN/A2.422.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDSAridis Pharmaceuticals9.65%EFTReFFECTOR Therapeutics57.67%NAVBNavidea Biopharmaceuticals0.01%TRVNTrevena13.56%Insider OwnershipCompanyInsider OwnershipARDSAridis Pharmaceuticals5.50%EFTReFFECTOR Therapeutics4.70%NAVBNavidea Biopharmaceuticals43.68%TRVNTrevena2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDSAridis Pharmaceuticals3053.32 million50.39 millionNot OptionableEFTReFFECTOR Therapeutics104.70 million4.48 millionNo DataNAVBNavidea Biopharmaceuticals10100.08 million56.37 millionNo DataTRVNTrevena40959,000841,000No DataEFTR, ARDS, TRVN, and NAVB HeadlinesRecent News About These CompaniesTrevena Restructures China Royalty Rights to Exit DebtJanuary 14, 2026 | tipranks.comSoftball: Conrad Weiser’s Alex Trevena earns statewide player of the year award; 5 other Berks players honoredJuly 8, 2025 | msn.comTrevena, Inc. (TRVN) - Yahoo FinanceJune 29, 2025 | finance.yahoo.comTrevena Enters Securities Exchange Agreement with InvestorMay 15, 2025 | tipranks.comBerks sports roundup: Alex Trevena helps Conrad Weiser to 8-5 softball winApril 11, 2025 | readingeagle.comRVanessa Hudgens and Oliver Trevena Appear at Expo West for CaliwaterMarch 9, 2025 | msn.comJMP Securities downgrades Trevena (TRVN) to a HoldDecember 27, 2024 | markets.businessinsider.com‘Plane’ Actor Oliver Trevena Signs With Untitled EntertainmentDecember 16, 2024 | yahoo.comLyme Regis town councillor John Trevena stand downDecember 11, 2024 | bridportnews.co.ukBTrevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock NowDecember 10, 2024 | zacks.comTrevena appoints new financial chiefNovember 29, 2024 | investing.comTrevena Appoints Katrine Sutton as New CFONovember 27, 2024 | tipranks.comHC Wainwright & Co. Downgrades Trevena (TRVN)November 16, 2024 | msn.comTrevena, Inc. Navigates Financial Challenges and Strategic ChangesNovember 9, 2024 | msn.comChester County biopharm firm's latest layoffs impact its C-suiteNovember 7, 2024 | bizjournals.comTrevena teeters in dangerous territory, terminating CEO and other execs amid strategic reviewNovember 7, 2024 | fiercebiotech.comFTrevena Reports Third Quarter 2024 Results and Provides Business UpdateNovember 7, 2024 | globenewswire.comWhy Trevena (TRVN) Stock Is Down 43% TodayOctober 8, 2024 | msn.comTrevena, Inc. Faces Delisting from NasdaqOctober 6, 2024 | msn.comTrevena Announces Receipt of Nasdaq Delisting NotificationOctober 4, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 2026Apple’s Earnings Make $300 Look Like a Matter of When, Not IfBy Sam Quirke | May 1, 20263 Ways to Invest in the Growing GLP-1 Weight Loss MarketBy Nathan Reiff | April 17, 2026NVIDIA’s China Connection: Investor Risks With Earnings AheadBy Thomas Hughes | May 5, 2026CPI Card Group’s Quiet Cash Machine Faces a Digital Reality CheckBy Peter Frank | May 4, 2026EFTR, ARDS, TRVN, and NAVB Company DescriptionsAridis Pharmaceuticals NASDAQ:ARDS$0.0028 +0.00 (+1,300.00%) As of 03:52 PM EasternAridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.eFFECTOR Therapeutics NASDAQ:EFTR$0.0002 0.00 (0.00%) As of 05/4/2026eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.Navidea Biopharmaceuticals NYSE:NAVBNavidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.Trevena NASDAQ:TRVN$0.01 0.00 (0.00%) As of 05/1/2026 09:33 AM EasternTrevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
